




Healthcare Industry News: Titan Spine
News Release - November 17, 2010
Titan Spine Receives Regulatory Clearance to Launch Endoskeleton(R) TO PLIF and Oblique Interbody Fusion Devices
Unique Implant Surface Participates in the Fusion ProcessMEQUON, Wis.--(Healthcare Sales & Marketing Network)-- Titan Spine, a developer of novel interbody fusion implants, announced today that it has received FDA clearance to commercially release its Endoskeleton® TO system, which consists of a line of interbody devices placed through a Posterior Lumbar Interbody Fusion (PLIF) approach. The company plans to commercially release the product beginning in December, 2010.
This is the fourth regulatory clearance for the company. “The Endoskeleton® TO incorporates the same innovative design features of our commercially-available cervical, ALIF and TLIF devices – a unique roughened Titanium surface that participates in the fusion process,” commented Chad Patterson, Director of Product Development and Operations for Titan Spine. “We chose to use Titanium due to its affinity to integrate with bone and its track record of success in other orthopedic applications. We feel the design and composition of our implants help to promote earlier bony ingrowth and stability in comparison to other available materials, thus leading to improved outcomes for our patients.”
About Titan Spine - Titan Spine, LLC is a privately owned company in Mequon, Wisconsin focusing on the design and manufacturing of bioactive interbody fusion devices for the spine. Founded in 2005, the company is committed to developing advanced products for treatment of various pathologies that cause back pain.
Source: Titan Spine
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.